Drug-labels.com

Pregvit (Duchesnay, 250 Unit / 300 mg / 1.6 mg / 13.8 mg..., 1.6 mg / 13.8 mg / 120 mg / 3 mg / 3....): Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Current status: Cancelled Post Market
Strength:
250 UNIT / 300 MG / 1.6 MG / 13.8 MG / 120 MG / 3 MG / 3.4 MG / 20 MG / 10 MG / 5 MG / 50 MG / 0.15 MG / 35 MG / 2 MG / 15 MG / 1.1 MG / 12 MCG, 1.6 MG / 13.8 MG / 120 MG / 3 MG / 3.4 MG / 20 MG / 10 MG / 5 MG / 50 MG / 0.15 MG / 35 MG / 2 MG / 15 MG / 5 MG / 12 MCG / 250 UNIT / 300 MG
Active ingredients:
ATC code:
Similar drugs:

Source: Health Canada – Drug Product Database (DPD) and product monographs · About this document

Patient Medication Information: uses, side effects, how to take - Pregvit (Duchesnay, 250 Unit / 300 mg / 1.6 mg / 13.8 mg..., 1.6 mg / 13.8 mg / 120 mg / 3 mg / 3....)

ABOUT THIS MEDICATION

What the medication is used for:

PregVit® is a vitamin-mineral supplement specially formulated for use in women at least 2-3 months prior to conception, throughout pregnancy and during the postnatal period. Taking PregVit® does not eliminate the need for a balanced nutrition.

What it does:

PregVit® provides a supplement of vitamins and minerals.

There is strong evidence that preventative treatment with folic acid, prior to and during pregnancy, can reduce the risk of fetal neural tube defects (NTDs). NTDs result from improper development and closure of the neural tube during the third and fourth week of development. Pregnancies affected by a NTD may result in a miscarriage or stillbirth, and children born with a NTD may have mild to severe disability or die in early childhood.

Although the use of a folic acid supplement from before conception to early pregnancy reduces the number of NTDs, they can not be completely avoided through folate supplementation because of their various origins. For women who had a prior history of an NTD pregnancy, the recurrence rate of another NTD pregnancy is 2-3%.

There is evidence that increasing the diet with an additional 0.4 mg/day of folic acid would reduce the risk of neural tube defects for all women planning a pregnancy by about 36%, 1 mg per day would reduce the risk by about 57% and the use of 1.1 mg daily would reduce the risk by about 59%.

When it should not be used:

You should not take PregVit® if you are allergic to any of the ingredients of PregVit® or component of the container (see list of medicinal and nonmedicinal ingredients below this section).

What the medicinal ingredients are:

Each oval shaped, pink (a.m.), film-coated, immediate release tablet contains:

Beta-Carotene (source of vitamin A) 2700 IU Vitamin B1 (thiamine mononitrate) 3 mg Vitamin B2 (riboflavin) 3.4 mg Niacinamide 20 mg Pantothenic Acid (calcium pantothenate) 5 mg Vitamin B6 (pyridoxine HCl) 10 mg Vitamin C (ascorbic acid) 120 mg Vitamin E (dl-alpha tocopheryl acetate) 30 IU Copper (cupric oxide) 2 mg Iodine (potassium iodide) 0.15 mg Iron (ferrous fumarate)* 35 mg Magnesium (magnesium oxide) 50 mg Zinc (zinc oxide) 15 mg

* Elemental amount

Each oval shaped, blue (p.m.), film coated, immediate release tablet contains:

Folic Acid 1.1 mg Vitamin B12 (cyanocobalamin) 12 µg Vitamin D3 (cholecalciferol) 250 IU Calcium (calcium carbonate)* 300 mg

* Elemental amount

What the important nonmedicinal ingredients are: PregVit® pink (a.m.) tablet contains:

ammonium hydroxide, N-butyl alcohol, carnauba wax, D&C Red #27, FD&C Blue #1, FD&C Blue #2, FD&C Red #40, FD&C Yellow #6, isopropyl alcohol, macrogol/PEG 3350, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol, propylene glycol, shellac glaze, simethicone, sodium croscarmellose, sodium lauryl sulfate, starch (corn starch), talc, titanium dioxide.

PregVit® blue (p.m.) tablet contains:

ammonium hydroxide, N-butyl alcohol, carnauba wax, D&C Red #27, FD&C Blue #2, FD&C Red #40, FD&C Yellow #6, isopropyl alcohol, macrogol/PEG 3350, magnesium stearate, polyvinyl alcohol, propylene glycol, shellac glaze, simethicone, sodium croscarmellose, sodium lauryl sulfate, talc, titanium dioxide.

This product does not contain lactose, gliadin-gluten or tartrazine.

This product is certified Kosher 334 and Halal .

What dosage forms it comes in:

PregVit® is supplied in a 30-day blister pack containing 30 oval, pink (a.m.) tablets and 30 oval, blue (p.m.) tablets. Each tablet is imprinted with a pink image of a pregnant woman.

WARNINGS AND PRECAUTIONS

BEFORE you use PregVit® talk to your doctor or healthcare professional if:

  • You have a vitamin B12 deficiency. Folic acid should be taken with vitamin B12 in order to avoid potential problems of the nervous system. Any dose of folic acid over 1 mg per day may require monitoring for vitamin B12 by a doctor or healthcare professional.
  • You have seizure disorders controlled on anticonvulsant medications (e.g. carbamazepine, phenobarbital, phenytoin, primidone, valproic acid). You may have an increase in seizures when folic acid is taken.

Keep this product out of the reach of children. Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Each PregVit® pink (a.m.) tablet contains 35 mg of elemental iron. No iron is contained in the PregVit® blue (p.m.) tablet

INTERACTIONS WITH THIS MEDICATION

As with most medications, interaction with other drugs is possible.

Tell your doctor, pharmacist or healthcare professional if you are taking any other medications, including prescription, non-prescription or natural health products, or vitamin-mineral supplements.

In particular, the drugs that may interact with PregVit® include:

  • Thyroid hormone medications. Absorption of thyroid medications could be reduced if taken at the same time as iron or calcium supplements. Thyroid medications should be taken four hours before or after the pink (a.m.) and the blue (p.m.) tablets of PregVit®.
  • Dihydrofolate reductase inhibitors. Dihydrofolate reductase inhibitors (including sulphasalazine, trimethoprim, triamterene) inhibit the absorption and metabolism of folic acid.
  • Antiepileptic drugs. Antiepileptic drugs reduce folic acid absorption. Folic acid supplements have worsened seizure control in some people with epilepsy.

PROPER USE OF THIS MEDICATION

Usual dosage schedule:

Take one pink (a.m.) tablet every morning on an empty stomach, one hour before breakfast, with a glass of water. Do not take any food for one hour after taking the pink (a.m.) tablet to help the iron absorption. If you suffer from nausea and/or vomiting in the morning (morning sickness), take the pink (a.m.) tablet two hours or more after breakfast. Take one blue (p.m.) tablet every evening with a glass of water, within one hour of the evening meal to help calcium absorption.

This product is specifically prescribed for you based on your current state of health. Do not give it to others, even if you think they could benefit from taking it, and you yourself must not use it for any other condition than the one for which it was prescribed.

Tablets are not intended to be crushed or split. If you have difficulty swallowing tablets, let your doctor or healthcare professional know.

Special cases:

  • For women taking calcium rich food for breakfast, the PregVit® pink (a.m.) tablet may be taken two (2) hours or more after breakfast. Following administration of the pink (a.m.) tablet a wait of one (1) additional hour is recommended before eating in order to optimize the absorption of iron.
  • For women suffering from nausea and/or vomiting in the morning where it is difficult to take vitamin-mineral supplements on an empty stomach, the PregVit® pink (a.m.) tablet may be taken two (2) hours or more after breakfast. Following administration of the pink (a.m.) tablet a wait of one (1) additional hour is recommended before eating in order to optimize the absorption of iron.
  • For women taking levothyroxine hormone in the morning, it is recommended to take the PregVit® pink (a.m.) tablet at least four (4) hours apart to optimize the absorption of levothyroxine hormone. For women taking levothyroxine hormone at bedtime, it is recommended to take the PregVit® blue (p.m.) tablet at least four (4) hours apart to optimize the absorption of levothyroxine hormone.

Overdose:

In case of accidental overdose, contact a doctor or a regional Poison Control Centre immediately.

Do not exceed the recommended dose.

Missed dose:

When a dose has been missed, it should be taken as soon as possible and one pink (a.m.) and one blue (p.m.) tablet should be taken within a 24-hour period. It is recommended that PregVit® pink (a.m.) and blue (p.m.) tablets be taken at least four (4) hours apart in order to optimize the absorption of nutrients.

The prescribed dosing schedule should then continue as directed by doctor or healthcare professional.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Side effects: The most common adverse reactions associated with vitamin-mineral supplements are gastrointestinal symptoms such as constipation, diarrhea, nausea and gastric irritation.

This is not a complete list of side effects.

For any unexpected effects while taking PregVit®, contact your doctor, pharmacist or healthcare professional.

HOW TO STORE IT

Store at room temperature (15 to 30ºC).

Protect from moisture. Contact with moisture may produce surface discoloration or erosion of the tablet.

Keep in a safe place out of reach of children.

REPORTING SUSPECTED SIDE EFFECTS

To monitor drug safety, Health Canada through the Canada Vigilance Program collects information on serious and unexpected side effects of drugs. If you suspect you have had a serious or unexpected reaction to this drug you may notify Canada Vigilance:

By toll-free telephone: 866-234-2345

By toll-free fax 866-678-6789

Online: www.healthcanada.gc.ca/medeffect By email: CanadaVigilance@hc-sc.gc.ca

By regular mail:

Canada Vigilance National Office

Marketed Health Products Safety and Effectiveness Information Bureau

Marketed Health Products Directorate

Health Products and Food Branch

Health Canada

Tunney’s Pasture, AL 0701C

Ottawa ON K1A 0K9

NOTE: Should you require information related to the management of the side effect, please contact your health care provider before notifying Canada Vigilance. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full Product Monograph, prepared for healthcare professionals can be obtained by contacting the sponsor, Duchesnay Inc. at:

2925 Boul. Industriel

Laval, Quebec, Canada

H7L 3W9

Tel: 1-888-666-0611

Fax: 1-888-588-8508

Last revised: January 7, 2009.

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02246067

Revision date stated in the text: January 7, 2009

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Pregvit (Duchesnay, 250 Unit / 300 mg / 1.6 mg / 13.8 mg..., 1.6 mg / 13.8 mg / 120 mg / 3 mg / 3....)

Rx or OTC
Prescription (Rx)?
DIN 02246067, 02276194
Schedule(s) PRESCRIPTION
Active ingredient(s) Vitamin D3 (vitamin D3), Calcium (calcium carbonate), Beta-carotene, Vitamin E (DL-alpha tocopheryl acetate), Ascorbic acid (ascorbic acid), Vitamin B1 (thiamine mononitrate), Vitamin B2 (vitamin B2), Nicotinamide, Vitamin B6 (pyridoxine hydrochloride), D-pantothenic acid (calcium D-pantothenate), Magnesium (magnesium oxide), Iodine (potassium iodide), Iron (ferrous fumarate), Copper (cupric oxide), Zinc (zinc oxide), Folic acid, Vitamin B12 (vitamin B12)
Dosage form(s) Tablet
Route(s) of administration Oral
Drug class (WHO ATC)
  1. B Blood and blood forming organ drugs
    1. B03 Antianemic preparations
      1. B03A Iron antianemic preparations
        1. B03AE Iron in other combinations
          1. B03AE04 Iron, multivitamins and minerals
Company DUCHESNAY INC
Current status Cancelled Post Market
Current status date July 5, 2016
Strengths and forms
DIN Strength Dosage form(s) Current status
02246067 250 UNIT / 300 MG / 1.6 MG / 13.8 MG / 120 MG / 3 MG / 3.4 MG / 20 MG / 10 MG / 5 MG / 50 MG / 0.15 MG / 35 MG / 2 MG / 15 MG / 1.1 MG / 12 MCG Tablet Cancelled Post Market July 5, 2016
02276194 1.6 MG / 13.8 MG / 120 MG / 3 MG / 3.4 MG / 20 MG / 10 MG / 5 MG / 50 MG / 0.15 MG / 35 MG / 2 MG / 15 MG / 5 MG / 12 MCG / 250 UNIT / 300 MG Tablet Cancelled Post Market July 5, 2016

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.